SMMT (STOCKS)
Summit Therapeutics Inc. Common Stock
$15.180000
-0.070000 (-0.46%)
Prev close: $15.250000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Robert William Duggan
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $11,549.66M
- Employees
- 159
- P/E (TTM)
- -12.28
- P/B (TTM)
- 59.05
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
13
Buy
4
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.31 | $-0.13 | -0.1755 | -130.48% |
|
Jun 2025 (Q2)
|
$-0.12 | $-0.10 | -0.0236 | -24.48% |
|
Mar 2025 (Q1)
|
$-0.09 | $-0.09 | +0.0028 | +3.02% |
|
Dec 2024 (Q4)
|
$-0.08 | $-0.08 | +0.0031 | +3.73% |
Financial Statements
| Nonoperating Income/Loss | $13.51M |
| Operating Expenses | $935.43M |
| Income/Loss From Continuing Operations After Tax | -$921.62M |
| Income/Loss From Continuing Operations Before Tax | -$921.62M |
| Net Income/Loss | -$921.62M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$921.62M |
| Net Income/Loss Available To Common Stockholders, Basic | -$921.62M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.25 |
| Diluted Earnings Per Share | -$1.25 |
| Basic Average Shares | 1,490,147,476 |
| Diluted Average Shares | 1,490,147,476 |
| Assets | $261.73M |
| Current Assets | $246.47M |
| Noncurrent Assets | $15.26M |
| Fixed Assets | $810.00K |
| Other Non-current Assets | $14.45M |
| Liabilities | $69.47M |
| Current Liabilities | $64.93M |
| Accounts Payable | $22.25M |
| Wages | $10.97M |
| Other Current Liabilities | $31.72M |
| Noncurrent Liabilities | $4.54M |
| Equity | $192.26M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $192.26M |
| Liabilities And Equity | $261.73M |
| Net Cash Flow From Operating Activities | -$269.67M |
| Net Cash Flow From Operating Activities, Continuing | -$269.67M |
| Net Cash Flow From Investing Activities | $394.33M |
| Net Cash Flow From Investing Activities, Continuing | $394.33M |
| Net Cash Flow From Financing Activities | $20.10M |
| Net Cash Flow From Financing Activities, Continuing | $20.10M |
| Net Cash Flow | $144.76M |
| Net Cash Flow, Continuing | $144.76M |
| Comprehensive Income/Loss | -$921.55M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$922.02M |
| Other Comprehensive Income/Loss | -$292.93M |